Nebivolol
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Nebivolol: Malignant hypertensive renal disease
One-Sentence Summary
Nebivolol is a third-generation beta-blocker, originally used to treat hypertension. The TxGNN model predicts it may be effective for malignant hypertensive renal disease, but no clinical trials and no publications currently support this specific prediction. The score most likely reflects its similarity to the already-approved hypertension indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Malignant hypertensive renal disease |
| TxGNN Prediction Score | 0.9942 |
| Evidence Level | L5 (model prediction only) |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. From general pharmacology, nebivolol is a highly beta-1-selective blocker that also promotes nitric oxide-mediated vasodilation. Its efficacy in hypertension is established.
Other predicted indications (for context):
| Rank | Predicted Indication | Score | Evidence Level | Comment |
|---|---|---|---|---|
| 2 | Malignant hypertensive renal disease | 0.9942 | L5 | Theoretical blood pressure-lowering benefit. Rodent renoprotection data come from other indications. |
| 3 | Pulmonary hypertension owing to lung disease and/or hypoxia | 0.9939 | L5 | Only indirect preclinical and beta-blocker safety literature. Beta-blockers are generally not recommended in pulmonary arterial hypertension, so a safety signal must be excluded first. |
| 4 | Pulmonary hypertension, unclear multifactorial mechanism | 0.9939 | L5 | No evidence. Risk of reduced right ventricular output. |
| 5 | Braddock syndrome | 0.9914 | L5 | No identifiable mechanistic link. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. |
Clinical Trial Evidence
Currently no related clinical trials registered for malignant renovascular hypertension.
For context, trials were found for other predicted indications:
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00517725 | Phase 4 | Completed | 60 | Nebivolol vs bisoprolol vs carvedilol in heart failure: effects on exercise capacity, hypoxia, chemoreceptor response and pulmonary function. Relevant to chronic pulmonary heart disease only indirectly. |
| NCT06424834 | Phase 2/3 | Recruiting | 150 | Targeted medical therapy vs placebo for angina with non-obstructive coronary arteries (MVP-ANOCA). It is unclear whether nebivolol is an arm, and no results are available. Indirect relevance to Prinzmetal angina. |
No ANZCTR identifiers were available in the data compiled for this report.
Literature Evidence
No literature is available for malignant hypertensive renal disease. The most relevant publications found for other predicted indications are below (all indirect).
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23506636 | 2013 | Randomised comparative study | Int J Cardiol | CARNEBI: carvedilol vs nebivolol vs bisoprolol in moderate heart failure. |
| 21883997 | 2012 | RCT | Cardiovasc Ther | Nebivolol vs carvedilol on exercise performance at high altitude in healthy subjects. |
| 15031571 | 2004 | Clinical study | Respiration | Nebivolol vs nifedipine over two weeks in hypertensive patients with COPD. |
| 21516766 | 2011 | Clinical study | Klin Med | Nebivolol in coronary heart disease with COPD (n=50): lowered blood pressure and heart rate, with no adverse effect on bronchial patency. |
| 19815121 | 2009 | Review | J Am Coll Cardiol | Nebivolol as a third-generation beta-blocker with endothelial NO-mediated effects. |
| 30426333 | 2018 | Review | Drugs | Nebivolol and its fixed-dose combinations in hypertension. |
| 29159953 | 2018 | Cohort | Eur J Heart Fail | Beta-blocker use in heart failure with concurrent COPD in Denmark. |
| 32128711 | 2020 | Preclinical (animal) | Pharmacol Rep | Renal protective effect of nebivolol in rat acute renal injury models. |
| 36947849 | 2023 | Preclinical (animal) | Can J Physiol Pharmacol | Nebivolol protected against methotrexate nephrotoxicity in rats. |
| 34693844 | 2022 | Preclinical (animal) | Drug Chem Toxicol | Nebivolol alleviated methotrexate liver damage in rats. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13441K | APO-Nebivolol | Tablet 10 mg (as hydrochloride) | Not stated in the data compiled for this report |
Only the oral route is available (tablet).
Safety Considerations
Product Information warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for label safety information.
Knowledge-graph contraindication signals (not label text) include:
- Liver failure, liver disease, gallbladder disease
- Diabetes mellitus, diabetic ketoacidosis, hypoglycaemia
- Peripheral vascular disease, intermittent claudication, peripheral arterial disease
- Atrioventricular block, sick sinus syndrome (including familial)
- Bronchial disease
Drug interactions: 100 interactions were identified in the data compiled for this report. The main ones listed are mostly Moderate:
- Epinephrine, morphine, bupropion, lorcaserin
- Corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide)
- Anticholinergics (atropine, hyoscyamine, glycopyrronium, dicyclomine)
- Antidiabetics (canagliflozin, dapagliflozin, chlorpropamide)
- Calcium acetate and calcium phosphate
Minor interactions include acetylsalicylic acid and magnesium oxide.
Indication-specific cautions: In pulmonary hypertension, beta-blockade may reduce right ventricular output. In vasospastic angina, the safety of nebivolol is unestablished.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for malignant hypertensive renal disease rests on model score alone (L5), with no trials or publications. The score is likely inflated by similarity to nebivolol’s approved hypertension indication.
To proceed, the following is needed:
- Mechanism of action data (for example from DrugBank)
- TGA Product Information warnings and contraindications (a blocking gap for safety screening)
- Targeted literature review on beta-blockers in renovascular and malignant hypertension
- Clinical evidence (observational or trial) in the predicted indication
- Clarification of the approved indication text for the ARTG entry
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.